nach oben

Drugs

Erschienen in:

01.01.2004 | Therapy In Practice

Restless Legs Syndrome

An Update on Treatment Options

verfasst von: Professor Anthony H. V. Schapira

Erschienen in: Drugs | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Restless legs syndrome (RLS) was first described in 1672 but it is only recently that this disorder has attracted attention in defining its phenotype, and identifying its aetiology, pathogenesis and pharmacological treatment. RLS can be divided into primary (idiopathic) and secondary forms. RLS is common, affecting 5–15% of the total population and manifesting at any age from childhood to late adulthood. Prevalence tends to increase with patient age and there may be geographic variation. There is a clear genetic contribution to primary RLS and evidence for dopaminergic dysfunction.

Although not all patients with RLS require medication, there can be a substantial reduction in the patient's quality of life related to pain, poor sleep and excessive daytime sleepiness. A variety of medications are now available for the symptomatic treatment of RLS. Dopaminergic therapy is currently the treatment of choice, usually initiated with a long-acting dopamine agonist, thereby avoiding some of the complications associated with levodopa. Anticonvulsants may be used as second-line treatment. Levodopa should be reserved for those patients who fail to respond to alternative medications because of the high risk of inducing augmentation. Hypnosedatives also have a role in RLS management. Patients with intractable RLS may require combination treatment. Several systemic disorders can cause RLS, and these should be identified and treated appropriately.

Willis T. De Animae Brutorum. London: Wells and Scott, 1672

Ekbom K. Restless legs: clinical study of hitherto overlooked disease in legs characterized by peculiar paresthesia (‘Anxietas tibiarum’), pain and weakness and occurring in two main forms, asthenia crurum paraesthetica and asthenia crurum dolorosa. Acta Med Scand 1945; 158: 5

Allen RP, Picchietti D, Henning WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 2003; 4: 101–19PubMedCrossRef

Birmann-Urbaneck M, Sanner B, Laschewski F, et al. Sleep disorders in patients with dialysis-dependent renal failure. Pneumologie 1995; 49 Suppl. 1: 158–60

Collado-Seidel V, Kohnen R, Samtleben W, et al. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis 1998; 31: 324–8PubMedCrossRef

Strang R. The symptoms of restless legs. Med J Aust 1967; 1: 1211–3PubMed

Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160: 2137–41PubMedCrossRef

Ulfberg J, Nystrom B, Carter N, et al. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001; 16: 1159–63PubMedCrossRef

Ulfberg J, Nystrom B, Carter N, et al. Restless legs syndrome among working-aged women. Eur Neurol 2001; 46: 17–9PubMedCrossRef

10.

Rotcach A, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Neurology 2000; 54: 1064–8CrossRef

11.

Tan E, Seah A, See S, et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001; 16: 577–9PubMedCrossRef

12.

Hui D, Wong T, Ko F, et al. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 36(4): 783–8PubMedCrossRef

13.

Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997; 12: 61–5PubMedCrossRef

14.

Winkelmann J, Wetter T, Collado-Seidel V, et al. Frequency and characteristics of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000; 23: 597–602PubMed

15.

Walters A, Hickey K, Maltzman J, et al. A questionnaire study of 138 patients with restless legs syndrome: the night-walkers-survey. Neurology 1996; 46: 92–5PubMedCrossRef

16.

Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996; 47: 1435–41PubMedCrossRef

17.

Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients: an American Academy of Sleep Medicine Review. Sleep 1999; 22: 970–99PubMed

18.

Winkelmann J, Wetter WC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000; 23: 597–602PubMed

19.

Ondo W, Vuong K, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000; 55: 1404–6PubMedCrossRef

20.

Lazzarini A, Walters A, Hickey K, et al. Studies of penetrance and anticipation in five autosomal-dominant restless legs syndrome pedigrees. Mov Disord 1999; 14: 111–6PubMedCrossRef

21.

Trenkwalder C, Seidel V, Gasser T, et al. Clinical symptoms and possible anticipation in a large kindred of familial restless legs syndrome. Mov Disord 1996; 11: 389–94PubMedCrossRef

22.

Desautels A, Turecki G, Montplaisir J, et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001; 69: 1266–70PubMedCrossRef

23.

Desautels A, Turecki G, Montplaisir J, et al. Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis. Neurology 2001; 57: 1034–6CrossRef

24.

Bonati MT, Ferini-Strambi L, Aridon P, et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003; 126: 1485–92PubMedCrossRef

25.

Trenkwalder C, Walters A, Hening W, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999; 14: 141–5PubMedCrossRef

26.

Turjanski N, Lees A, Brooks D, et al. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52: 932–7PubMedCrossRef

27.

Eisensehr I, Wetter T, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57: 1307–9PubMedCrossRef

28.

Ruottinen H, Partinen M, Hublin C, et al. An F-DOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54: 502–4PubMedCrossRef

29.

San Pedro E, Mountz J, Mountz J, et al. Familial painful restless legs syndrome correlates with pain dependant variation of blood flow to the caudate, thalamus and anterior cingulate gyrus. J Rheumatol 1998; 25(11): 2270–5

30.

Michaud M, Soucy J, Chabli A, et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002; 249(2): 164–70PubMedCrossRef

31.

Mrowka M, Joebges M, Berding G, et al. Clinical investigations, computerized movement analysis and striatal dopamine transporter function in restless legs syndrome. J Neural Transm 2001; 108: 120

32.

Early CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000; 54: 1698–700CrossRef

33.

Tarquini B. Iron metabolism: clinical chronobiological aspects. Chronobiologia 1978; 5: 315–36PubMed

34.

Allen R, Barker P, Wehr F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001; 56: 263–5PubMedCrossRef

35.

Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003; 61(3): 304–9PubMedCrossRef

36.

Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982; 39: 739PubMedCrossRef

37.

Akpinar S. Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 1987; 10: 69–79PubMedCrossRef

38.

Brodeur C, Montplaisir J, Godbout R, et al. Treatment of restless legs syndrome and periodic movements during sleep with L-Dopa: a double-blind controlled study. Neurology 1988; 38: 1845–8PubMedCrossRef

39.

von Scheele C. Levodopa in restless legs. Lancet 1986; II: 426–7CrossRef

40.

von Scheele C, Kempi V. Long-term effect of dopaminergic drugs in restless legs: a 2-year follow-up. Arch Neurol 1990; 47: 1223–4CrossRef

41.

Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993; 43: 445PubMedCrossRef

42.

Allen R, Kaplan P, Buchholz D, et al. A double-blind, placebo controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993; 16: 717–23PubMed

43.

Collado-Seidel V, Kazenwadel J, Wetter T, et al. A controlled study of additional sr.L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999; 52: 225–90CrossRef

44.

Allen R, Earley C. Augmentation of the restless legs syndrome. Sleep 1996; 19: 205–13PubMed

45.

Walters A, Hening W, Kavey N, et al. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988; 24: 455–8PubMedCrossRef

46.

Becker P, Jamieson A, Brown W. Dopaminergic agents in restless legs syndrome and periodic leg movements in sleep: response and complications of extended treatment in 49 cases. Sleep 1993; 16: 713–6PubMed

47.

Wetter T, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999; 52: 944–50PubMedCrossRef

48.

Earley C, Allen R. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996; 19: 801–10PubMed

49.

Stiasny K, Wetter T, Winkelmann J, et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001; 56: 1399–402PubMedCrossRef

50.

Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999; 52: 938–843PubMedCrossRef

51.

Lin S, Kaplan J, Burger C, et al. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998; 73(6): 497–500PubMedCrossRef

52.

Becker P, Ondo W, Sharon D. Encouraging initial response of restless legs syndrome to pramipexole. Neurology 1998; 51: 1221–3PubMedCrossRef

53.

Stiasny K, Robbecke J, Schuler P, et al. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline: an open clinical trail. Sleep 1999; 23: 349–54

54.

Saletu M, Anderer P, Hauer C, et al. Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2: findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 2000; 41: 190–9

55.

Ondo WG. Ropinirole for restless legs syndrome. Mov Disord 1999; 14: 890–2

56.

Galvez-Jimenez N, Khan T. Ropinirole and restless legs syndrome. Mov Disord 1999; 14: 138–40CrossRef

57.

Reuter I, Ellis C, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand 1999; 100: 163–7PubMedCrossRef

58.

Ekbom KA. Restless legs. Swed Med J 1965; 62: 2376–82

59.

Morhan LK. Restless limbs: a commonly overlooked symptom controlled by ‘Valium’. Med J Aust 1967; 2: 589–94

60.

Montplaiser J, Godbout R, Boghen D, et al. Familial restless legs with periodic movements in sleep: electrophysiologic, biochemical, and pharmacologic study. Neurology 1985; 35: 130–4CrossRef

61.

Read DJ, Feest TG, Nassim NA. Clonazepam: effective treatment for restless legs syndrome in uraemia. BMJ 1981; 283: 885–6PubMedCrossRef

62.

Boghen D, Lamothe L, Elie R, et al. The treatment of restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986; 13: 245–7PubMed

63.

Montagna P, Sassoli de Bianchi L, Zucconi M, et al. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984; 69: 428–30PubMedCrossRef

64.

Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs: A controlled pilot study. Eur J Clin Pharmacol 1983; 25: 323–4PubMedCrossRef

65.

Telstad W, Sorensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. BMJ 1984; 288: 444–6PubMedCrossRef

66.

Allen R, Earley C. An open label clinical trial with structured subjective reports and objective leg activity measures comparing gabapentin with alternative treatment in the restless legs syndrome [abstract]. Washington, DC: Association of Professional Sleep Societies, 1996: 95

67.

Mellick G, Mellick L. Management of restless legs syndrome with gabapentin (Neurontin) [letter]. Sleep 1996; 19: 224–6PubMed

68.

Adler C. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol 1997; 20: 148–51PubMedCrossRef

69.

Uhles M, Duntley S. Evaluation of the efficacy of Neurontin in the treatment of restless legs syndrome. Sleep 1999; 22 Suppl. 1: s157

70.

Garcia-Borreguero D, Larrosa O, et al. Treatment of RLS with gabapentin: a double-blind cross-over study. Neurology 2002; 59: 1573–9PubMedCrossRef

71.

Handwerker JV, Palmer RF. Clonidine in the treatment of restless legs syndrome. N Engl J Med 1985; 313: 1228–9PubMedCrossRef

72.

Wagner ML, Walters AS, Coleman RG, et al. Randomized, double-blind placebo controlled study of clonidine in restless legs syndrome. Sleep 1996; 19: 52–8PubMed

73.

Bamford CR, Sandyk R. Failure of clonidine to ameliorate the symptoms of restless legs syndrome. Sleep 1987; 10: 398–9PubMed

74.

Walters AS, Wagner NE, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double blind trial of oxycodone versus placebo. Sleep 1993; 16(4): 327–32PubMed

75.

Kaplan PW, Allen RP, Buchholz DW, et al. A double blind, placebo controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993; 16: 717–23PubMed

76.

Walters A, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001; 16: 1105–9PubMedCrossRef

Titel: Restless Legs Syndrome
An Update on Treatment Options
verfasst von: Professor Anthony H. V. Schapira
Publikationsdatum: 01.01.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 2/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464020-00003

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Restless Legs Syndrome

An Update on Treatment Options

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2004

Management of Osteoporosis in Adults with Cystic Fibrosis

Myelopathy in Sjögren’s Syndrome

Efflux-Mediated Drug Resistance in Bacteria

Atomoxetine